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Summary
The majority of the global population of sickle cell disease
(SCD) patients resides in Africa. Individuals with this condi-
tion are at great risk of serious infections and early mortality
secondary to splenic dysfunction without preventative mea-
sures. This review investigated the spectrum of splenic compli-
cations encountered in SCD among populations in Africa. We
systematically searched several databases for all articles pub-
lished through March 3, 2020. We included 55 studies from 14
African countries. This review reveals the difference in fre-
quency of splenic complications in SCD in Africa when com-
pared with their counterparts in the United State and Europe.
While several studies (n = 45) described splenomegaly with a
prevalence of 12% to 73% among children, and 4% to 50%
among adults with HbSS, the reported prevalence for acute
splenic sequestration crisis (n = 6 studies) and hypersplenism
(n = 4 studies) was <10% and <5% respectively. A total of 30
surgical splenectomy was reported across eight studies. Only
two (3.7%) studies provided data on spleen function. A con-
flicting pattern was observed amongst studies that evaluated
the relationship between splenomegaly and the presence of
bacterial and malaria infections. This review reveals the paucity
of studies describing the role of SCD-induced splenic dysfunc-
tion in morbidity and infection related mortality in Africa.
Keywords: sickle cell disease, spleen, complications, spleno-
megaly, infections, Africa.
About two-thirds of the global population of patients with
sickle cell disease (SCD) reside in Africa,1,2 and an estimated
50–90% of children born with SCD in Sub-Saharan Africa
die before their fifth birthday.3 This high mortality has partly
been attributed to infections secondary to splenic
dysfunction.4,5 The repeated cycle of vaso-occlusion and
ischaemia leads to progressive fibrosis, atrophy and
autosplenectomy. Therefore, the spleen is rarely palpable
beyond the age of 5 years in patients with SCD in the USA
and Europe.6,7 However, enlargement of the spleen (spleno-
megaly) tends to persist into late childhood or even adult-
hood in patients with SCD in Africa; earlier studies have
linked this finding to the effect of malaria infection in a
manner similar to what is observed in patients with the
hyper-reactive malarial splenomegaly syndrome.8,9 Also, per-
sistently high level of fetal haemoglobin (HbF), co-inheri-
tance of alpha thalassaemia trait and presence of other
compound heterozygous forms of SCD have been attributed
to the persistence of splenomegaly.10–12 The enlarged spleen
may be complicated by worsening anaemia due to trapping
of blood within the spleen13,14 and haemolytic crisis.15 Other
serious complications are acute splenic sequestration crisis
(ASSC), massive splenic infarction, splenic abscess and
hypersplenism, some of which may require splenectomy.10,16–
18
The spleen serves as the major filter for blood of senescent
red cells and micro-organisms, and is involved in both
humoral and innate immunity.19–21 The spleen parenchyma is
divided into a white- and red-pulp compartment and separat-
ing these two is the marginal zone. The white pulp corre-
sponds to the T and B lymphocyte cells zone and is
responsible for adaptive immunity. Within the marginal zone,
cells interaction and cell–cell sorting takes place; specialised
marginal zone B lymphocyte cells respond to capsule polysac-
charide antigens by differentiating into immunoglobulin M
(IgM)-producing memory B cells. The red pulp is mainly
responsible for the filtration function of the spleen; immature,
damaged, or ageing red cells adhere to the reticular meshwork
in this zone through specific signals or are captured by the
macrophages and prevented from circulating again.19
At birth, the spleen appears morphologically and function-
ally normal in patients with SCD. The sequence of events
that results in splenic injury begins following the haemoglo-
bin switch that occurs at ~6 months of age.7 The blood flow
within the red pulp is particularly slow; the resulting high
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haematocrit promotes red cell stagnation, leading to hypoxia,
acidosis, and further sickling of the red cells. Splenic dys-
function develops from blockage of the small inter-endothe-
lial slits within the sinuses by the stiff and sickled red cells.
An earlier study revealed that the phagocytic function
becomes impaired first, while the filtration function may per-
sist longer before it becomes compromised.22
Given the critical role the spleen plays in defence against
micro-organisms, the loss of splenic function contributes sig-
nificantly to the increased predisposition to bacterial infections
seen in patients with SCD.12,23 However, studies describing the
role of SCD-induced splenic dysfunction as a cause of morbid-
ity and mortality in patients with SCD in Africa are limited.
The objective of the present systematic review was to describe
and evaluate the existing data on the spectrum of splenic com-
plications and associated morbidities amongst patients with
SCD in Africa. The findings are a synthesis of the scarce infor-
mation available from Africa about the relationship between
size and function of the spleen, and the outcomes of SCD, and
can provide the basis for more rational strategies to manage
this common, chronic condition that places a high burden on
resource-limited health services across the continent.
Methods
Inclusion Criteria
The review comprised studies conducted across African
countries involving patients of all ages with SCD. For this
review, we defined SCD as HbSS, HbSC, HbSb+ thalassaemia,
or HbSb0 thalassaemia genotypes. We considered cross-sec-
tional studies (prospective, retrospective), case-control stud-
ies, case series and case reports on splenic complications, in
which the splenic complications were established through
clinical assessment, abdominal ultrasound scan (USS) and
other modalities. To be included in this review, articles
needed to have original data on at least one splenic compli-
cation as a primary or secondary outcome of the study. Arti-
cles in all languages were included. We excluded review
articles and studies conducted outside of Africa.
Search strategy
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.24 Four
databases were searched from the dates shown in parentheses
up to 3rd March 2020: the Medical Literature Analysis and
Retrieval System Online (MEDLINE; 1963), Global Health
Database (1973), Web of Science (1970) and Cumulative
Index to Nursing and Allied Health Literature (CINAHL;
2002). We used Boolean logic with search terms including
“sickle cell anaemia”, “spleen”, “splenic dysfunction”, and
“Africa south of Sahara”. We used controlled vocabularies
(e.g. Medical Subject Heading terms) to identify synonyms.
We did additional searches in other electronic resources
including Google Scholar and African Journals Online and
several grey literature resources including Google Advanced,
Electronic Theses Online Service (EThOS) library, Bielefeld
Academic Search Engine (BASE) search, Networked digital
library of thesis and dissertations, and open access theses and
dissertations. We screened the reference lists of all retrieved
articles for additional articles. Citations were uploaded into
an EndNote X9 library where duplicates were removed. We
applied no language restrictions to the search criteria and all
non-English articles (i.e. 10 in French) were translated.
Data extraction
Titles and abstracts of studies retrieved from the databases
and additional sources mentioned above were screened inde-
pendently by two investigators (A.I.L. and A.O.A.) for their
eligibility for full-text review. Differences of opinion were
settled through discussion with a third author (I.B.) until
consensus was achieved. Excluded studies were documented
with reasons. Data were extracted using a predefined pro-
forma that contained sections for authors, date of publica-
tion, location, study population, sample size, study design,
age, gender, and method of assessing spleen size and assess-
ment of spleen function. We also extracted laboratory data
on Hb; counts for white blood cells (WBCs), platelets and
reticulocytes; HbF; and the presence of malaria and bacterial
infections.
Quality assessment of studies
The Joanna Briggs Institute Critical Appraisal tools for
assessing the quality of observational studies were used.25
Two authors (A.I.L., A.O.A.) independently appraised each
article for quality using the following assessment criteria:
description of study selection criteria and population; ascer-
tainment of spleen size using a standard approach; reliable
and valid method for measuring exposure variables; identifi-
cation of confounding factors and strategies to deal with
them; definition of outcome and use of appropriate statistical
analysis. The quality of each of the criteria was assessed as
either ‘yes’ or ‘no’ or ‘unclear’ or ‘not applicable’. Points
were assigned to each ‘yes’ question for a total of 7 points.
Articles scoring 7 points were graded as ‘A’ quality, those
scoring 5–6 points as ‘B’ quality, and those scoring <5 as ‘C’
quality.
Data synthesis and analysis
Variations in the study populations (children, adults, mixed
population), study designs, methods of assessing spleen size
(manual palpation using different cut-off values, USS), and
reported outcomes in the studies retrieved made direct com-
parisons inappropriate, thus a descriptive method for data
synthesis was employed and a narrative approach used for
data analysis.
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Results
Search results
A total of 202 articles were identified in the initial search and 28
in the additional search. After removal of duplicates, 188 articles
remained. Their abstracts and titles were screened and 68 rele-
vant articles, which met the inclusion criteria, were selected for
full-text review; 55 studies were selected for inclusion into the
final review and 13 studies were excluded on the following
grounds: duplication of data (n = 3), reviews (n = 3), lack of
original data (n = 5), study outside Africa (n = 1) (Fig 1).
Another article was excluded because the authors inferred in the
abstract that changes in haematological parameters (raised
WBCs and platelets) were related to spleen effect; however, on
full-text review, the study design did not include evaluation of
the spleen. Of the 55 studies included in the systematic review
10 were in French and 45 in English.
General study description
The 55 studies were published between 1982 and 2019; 33 (600%)
had a cross-sectional design, 10 (182%) were retrospective
descriptive studies, 11 (200%) were case-control studies and one
(18%) was a case study (Table I)[8–9,13–15,26–70,101–105]. Following
quality assessment of all studies, seven (127%) were classified as
Grade A, 36 (655%) as Grade B, and the remaining 12 (218%) as
Grade C. The studies were conducted across 14 African countries.
Seven of the countries were from the West African region, three
from East Africa, and two each were from the Central and North
African region. However, most studies [33 (600%)] were con-
ducted in Nigeria, four (72%) were from the Democratic Repub-
lic of Congo (DRC) and two each (36%) from Congo, Senegal,
andGhana.
Of the studies from Nigeria, 17 (515%) were conducted
in the south western part of the country across various
institutions; four of these studies conducted between 1988
and 1993 were from a single author. The remaining 16
(485%) studies were conducted across various regions of
the country.
Description of methodologies used in the studies
Apart from two large cross-sectional studies (n = 2305 and
n = 4359), the sample size ranged between 40 and 591 for
the prospective cross-sectional studies and 25–300 for the
case-control studies. Whereas, 19 studies included children
and adults with SCD, 23 studies consisted of children only
and 13 adults only. In all, 32 studies included only individu-
als with HbSS, 12 had a combination of SCD genotypes (i.e.
HbSS, HbSC, HbS-b-thalassaemia (HbS-b-thal), and the
remaining 11 consisted of patients with HbSS and normal
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Fig. 1. Summary of data extraction. [Colour figure can be viewed at wileyonlinelibrary.com]
Review
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd 3
T
ab
le
I.
G
en
er
al
st
u
d
y
ch
ar
ac
te
ri
st
ic
s.
R
ef
er
en
ce
C
o
u
n
tr
y
St
u
d
y
si
ze
,
n
H
b
p
h
en
o
ty
p
e
M
ea
n
ag
e,
ye
ar
s
(S
D
,
ra
n
ge
)
H
b
,
g/
l/
P
C
V
,
%
,
m
ea
n
(S
D
)
H
b
F
le
ve
l,
%
,
m
ea
n
(S
D
)
Sp
le
en
si
ze
as
se
ss
m
en
t
Sp
le
n
o
m
eg
al
y,
%
St
u
d
y
d
es
ig
n
St
u
d
ie
s
in
vo
lv
in
g
ch
il
d
re
n
o
n
ly
(N
=
23
)
B
el
h
an
i
et
al
.,
19
84
4
8
A
lg
er
ia
84
H
b
S-
b
-t
h
al
0
H
b
S-
b
-t
h
al
+
H
b
SS
N
R
(N
R
,
<
15
)
H
b
:
H
b
S-
b
-t
h
al
0
:
82
(1
7)
H
b
S-
b
-t
h
al
+
:
10
2
(1
7)
H
b
SS
:
77
(1
5)
H
b
S-
b
-t
h
al
0
:
14
3
(8
9)
H
b
S-
b-
th
al
+
:
68
(3
7)
H
b
SS
:8
5
(8
3)
M
an
u
al
p
al
p
at
io
n
H
b
S-
b
-t
h
al
0
:
22
92
0
H
b
SS
:
34
0
C
as
e-
co
n
tr
o
l
st
u
d
y
A
d
ek
il
e
et
al
.,
19
88
8
N
ig
er
ia
13
9
H
b
SS
,
H
b
A
A
71
(4
2,
05
–1
5)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
33
8
C
as
e-
co
n
tr
o
l
st
u
d
y
O
ko
ro
et
al
.,
19
89
5
6
N
ig
er
ia
43
59
H
b
SS
N
R
C
N
A
N
A
M
an
u
al
p
al
p
at
io
n
N
R
C
C
ro
ss
se
ct
io
n
al
A
d
eo
d
u
an
d
A
d
ek
il
e,
19
90
1
5
N
ig
er
ia
25
H
b
SS
11
3
(2
9,
8
15
)
P
C
V
:
20
5(
24
)
N
A
M
an
u
al
p
al
p
at
io
n
H
b
SS
w
it
h
P
G
S
(1
5)
an
d
w
it
h
o
u
t
P
G
S
C
as
e-
co
n
tr
o
l
st
u
d
y
A
d
ek
il
e
et
al
.,
19
91
3
3
N
ig
er
ia
54
H
b
SS
,
H
b
A
S,
H
b
A
A
89
(N
R
,
3
7)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
25
0
C
as
e-
co
n
tr
o
l
st
u
d
y
D
o
u
m
b
o
et
al
.,
19
92
3
9
M
al
i
23
6
H
b
SS
,
H
b
A
A
-
N
A
N
A
M
an
u
al
p
al
p
at
io
n
12
0
C
ro
ss
se
ct
io
n
al
T
h
u
il
li
ez
et
al
.,
19
96
4
9
G
ab
o
n
30
2
H
b
SS
N
R
H
b
:
70
(N
R
)
N
A
M
an
u
al
p
al
p
at
io
n
33
0
C
ro
ss
se
ct
io
n
al
M
o
u
 el
 e
et
al
.,
19
99
6
6
R
ep
u
b
li
c
o
f
th
e
C
o
n
go
11
6
H
b
SS
94
(5
3,
1–
32
)
H
b
:
66
(1
4)
88
(5
8)
M
an
u
al
p
al
p
at
io
n
40
C
ro
ss
se
ct
io
n
al
A
m
b
e
et
al
.,
20
01
5
9
N
ig
er
ia
10
4
H
b
SS
N
R
(N
R
,
05
1
5)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
N
A
C
ro
ss
se
ct
io
n
al
G
o
u
ss
an
o
u
et
al
.,
20
03
5
8
R
ep
u
b
li
c
o
f
B
en
in
23
6
H
b
SS
M
ed
ia
n
29
(0
6–
12
)
H
b
:
78
(1
1)
P
C
V
:
25
3
(3
7)
10
1(
58
)
M
an
u
al
p
al
p
at
io
n
N
R
C
ro
ss
se
ct
io
n
al
A
w
o
tu
a-
E
fe
b
o
et
al
.,
20
04
6
9
N
ig
er
ia
10
0
H
b
SS
,
H
b
A
A
N
R
(N
R
,
05
1
5)
N
A
N
A
U
SS
27
0
C
o
m
p
ar
at
iv
e,
cr
o
ss
se
ct
io
n
al
D
ar
ko
et
al
.,
20
05
1
0
1
G
h
an
a
31
5
H
b
SS
,
H
b
SC
,
H
b
S-
b
-t
h
al
+
N
R
(N
R
,
2–
13
)
N
A
N
A
U
SS
N
R
C
ro
ss
se
ct
io
n
al
G
n
as
si
n
gb
e
et
al
.,
20
07
4
0
T
o
go
8
H
b
SS
,
H
b
SC
N
R
(N
R
,
8–
13
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
Y
es
,
n
=
5
(H
b
SS
3,
H
b
SC
2)
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
17
ye
ar
s
K
iz
it
o
et
al
.,
20
07
6
7
U
ga
n
d
a
15
5
H
b
SS
44
(N
R
,
03
1
48
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
36
0
C
ro
ss
se
ct
io
n
al
Sa
d
ar
an
ga
n
i
et
al
.,
20
09
5
0
K
en
ya
12
4
H
b
SS
63
(N
R
,
08
1
37
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
33
0
C
ro
ss
se
ct
io
n
al
D
ia
gn
e
et
al
.,
20
10
1
4
Se
n
eg
al
69
8
H
b
SS
,
H
b
SC
H
b
S-
b
-t
h
al
+
12
2(
N
R
,
07
–2
4)
H
b
:
80
(1
1)
83
(7
9)
M
an
u
al
p
al
p
at
io
n
H
b
SS
:
20
1
H
b
SC
:
41
9
H
b
S-
b-
th
al
+
:
57
1
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
15
ye
ar
s
B
ro
w
n
et
al
.,
20
12
4
4
N
ig
er
ia
41
5
H
b
SS
,
H
b
SC
73
(4
4,
05
1
7)
P
C
V
H
b
SS
:
24
(3
7)
H
b
SC
:
28
(4
5)
N
A
M
an
u
al
p
al
p
at
io
n
H
b
SS
:
31
7
H
b
SC
:
33
3
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
10
ye
ar
s
Review
4 ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd
T
ab
le
I.
(C
on
ti
n
u
ed
)
R
ef
er
en
ce
C
o
u
n
tr
y
St
u
d
y
si
ze
,
n
H
b
p
h
en
o
ty
p
e
M
ea
n
ag
e,
ye
ar
s
(S
D
,
ra
n
ge
)
H
b
,
g/
l/
P
C
V
,
%
,
m
ea
n
(S
D
)
H
b
F
le
ve
l,
%
,
m
ea
n
(S
D
)
Sp
le
en
si
ze
as
se
ss
m
en
t
Sp
le
n
o
m
eg
al
y,
%
St
u
d
y
d
es
ig
n
A
lo
n
i
et
al
.,
20
13
1
0
2
D
R
C
10
8
H
b
SS
M
ed
ia
n
54
(0
5–
13
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
37
8
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
10
ye
ar
s
A
b
d
u
ll
ah
i
et
al
.,
20
14
2
6
N
ig
er
ia
30
0
H
b
SS
,
H
b
A
A
N
R
(N
R
,
05
1
5)
H
b
:
73
(1
3)
46
(1
7)
U
SS
35
3
C
as
e-
co
n
tr
o
l
st
u
d
y
Sh
o
n
go
et
al
.,
20
14
4
2
D
R
C
20
5
H
b
SS
32
(1
4,
N
R
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
73
2
C
ro
ss
se
ct
io
n
al
A
d
eg
o
ke
et
al
.,
20
15
3
5
N
ig
er
ia
24
0
H
b
SS
,H
b
SC
59
(3
7,
05
1
5)
P
C
V
:1
87
(7
8)
N
A
M
an
u
al
p
al
p
at
io
n
H
b
SS
:
12
5
H
b
SC
:
43
C
ro
ss
se
ct
io
n
al
Y
ak
u
b
u
et
al
.,
20
17
1
0
3
]
N
ig
er
ia
20
0
H
b
SS
79
(4
,
1–
15
)
N
A
N
A
U
SS
53
5
C
ro
ss
se
ct
io
n
al
A
ki
n
lo
so
tu
et
al
.,
20
18
3
6
N
ig
er
ia
10
5
H
b
SS
73
(3
6,
N
R
)
H
b
:
77
(1
1)
P
C
V
:2
34
(2
2)
99
(6
)
C
o
m
b
in
ed
:
M
an
u
al
,
U
SS
26
0
C
ro
ss
se
ct
io
n
al
St
u
d
ie
s
in
vo
lv
in
g
ch
il
d
re
n
an
d
ad
u
lt
s
(N
=
19
)
K
ai
n
e,
19
82
5
1
N
ig
er
ia
21
0
H
b
SS
61
(N
R
,
08
1
9)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
<
5
ye
ar
s:
55
5–
10
ye
ar
s:
45
>
10
ye
ar
s:
18
C
ro
ss
se
ct
io
n
al
B
ay
o
u
m
i
et
al
.,
19
88
4
7
Su
d
an
50
H
b
SS
,
H
b
S-
b
-t
h
al
+
64
(N
R
,
05
–3
8)
H
b
:
73
(N
R
)
70
(N
R
)
M
an
u
al
p
al
p
at
io
n
42
0†
D
es
cr
ip
ti
ve
cr
o
ss
se
ct
io
n
al
A
d
ek
il
e
et
al
.,
19
93
3
4
N
ig
er
ia
41
0
H
b
SS
,
H
b
A
S,
H
b
A
A
97
(0
3,
1–
25
)
H
b
:
76
(N
R
)
93
(N
R
)
M
an
u
al
p
al
p
at
io
n
23
3
C
o
m
p
ar
at
iv
e
cr
o
ss
se
ct
io
n
al
T
sh
il
o
lo
et
al
.,
19
96
3
8
D
R
C
59
1
H
b
SS
N
R
,
(N
R
,
3–
12
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
44
4
C
ro
ss
se
ct
io
n
al
O
la
tu
n
ji
et
al
.,
20
01
4
6
N
ig
er
ia
98
H
b
SS
,
H
b
A
A
13
9
(7
4,
3–
47
)
N
A
N
A
U
SS
N
R
C
as
e-
co
n
tr
o
l
st
u
d
y
A
lu
fo
h
ai
an
d
O
d
u
sa
n
ya
,
20
06
6
1
N
ig
er
ia
17
H
b
SS
11
8
(N
R
,
10
1
5)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
N
A
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
12
ye
ar
s
M
ak
an
i
et
al
.,
20
10
6
8
T
an
za
n
ia
23
05
H
b
SS
M
ed
ia
n
11
(0
3–
47
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
10
0
C
ro
ss
se
ct
io
n
al
Je
b
b
in
an
d
A
d
o
te
y,
20
11
6
3
N
ig
er
ia
6
H
b
SS
N
R
(N
R
,
11
–2
0)
N
A
N
A
N
A
N
A
C
as
e-
st
u
d
ie
s
M
a’
aj
i
et
al
.,
20
12
1
0
4
]
N
ig
er
ia
71
H
b
SS
N
A
N
A
N
A
U
SS
21
1
C
ro
ss
se
ct
io
n
al
M
p
al
am
p
a
et
al
.,
20
12
6
4
U
ga
n
d
a
21
6
H
b
SS
93
(4
8,
1
18
)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
24
0
C
ro
ss
se
ct
io
n
al
A
kp
an
,
20
15
5
2
N
ig
er
ia
22
0
H
b
SS
12
1
(8
3,
1–
41
)
N
A
N
A
U
SS
23
C
ro
ss
se
ct
io
n
al
E
ze
et
al
.,
20
15
5
4
N
ig
er
ia
10
4
H
b
SS
,
H
b
SC
,
H
b
A
A
N
R
(N
R
,
2–
58
)
N
A
N
A
U
SS
33
0†
C
o
m
p
ar
at
iv
e
cr
o
ss
se
ct
io
n
al
T
h
ia
m
et
al
.,
20
17
6
0
Se
n
eg
al
46
H
b
SS
8,
(N
R
,
09
2–
21
)
H
b
:
86
(5
)
40
(N
R
)
M
an
u
al
p
al
p
at
io
n
21
7
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
2
ye
ar
s
In
ah
an
d
E
ka
n
em
,
20
18
3
1
N
ig
er
ia
12
0
H
b
SS
M
ed
ia
n
14
5
(6
–2
5)
N
A
N
A
U
SS
08
3
C
ro
ss
se
ct
io
n
al
L
u
n
ts
i
et
al
.,
20
18
3
0
N
ig
er
ia
12
6
H
b
SS
18
(6
3,
3–
38
)
N
A
N
A
U
SS
50
0
C
ro
ss
se
ct
io
n
al
U
gw
u
et
al
.,
20
18
5
3
N
ig
er
ia
23
7
H
b
SS
M
ed
ia
n
98
,
(1
–4
9)
N
A
N
A
U
SS
N
R
C
ro
ss
se
ct
io
n
al
B
an
za
et
al
.,
20
19
5
7
D
R
C
20
6
H
b
SS
11
8
(2
19
,
11
–3
8)
N
A
N
A
U
SS
13
1
R
et
ro
sp
ec
ti
ve
,
3
ye
ar
s
re
vi
ew
E
ze
ik
e,
20
19
2
8
N
ig
er
ia
10
0
H
b
SS
,
H
b
A
A
N
R
(N
R
,
0–
30
)
N
A
N
A
U
SS
31
0
C
as
e-
co
n
tr
o
l
st
u
d
y
K
az
ad
i
et
al
.,
20
19
4
1
D
R
C
25
6
H
b
SS
84
(4
9,
05
–2
4)
H
b
:
74
(1
5)
P
C
V
:
23
3
(4
5)
N
A
M
an
u
al
p
al
p
at
io
n
41
7
C
ro
ss
se
ct
io
n
al
Review
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd 5
T
ab
le
I.
(C
on
ti
n
u
ed
)
R
ef
er
en
ce
C
o
u
n
tr
y
St
u
d
y
si
ze
,
n
H
b
p
h
en
o
ty
p
e
M
ea
n
ag
e,
ye
ar
s
(S
D
,
ra
n
ge
)
H
b
,
g/
l/
P
C
V
,
%
,
m
ea
n
(S
D
)
H
b
F
le
ve
l,
%
,
m
ea
n
(S
D
)
Sp
le
en
si
ze
as
se
ss
m
en
t
Sp
le
n
o
m
eg
al
y,
%
St
u
d
y
d
es
ig
n
St
u
d
ie
s
in
vo
lv
in
g
ad
u
lt
s
o
n
ly
(N
=
13
)
B
ed
u
-A
d
d
o
an
d
B
at
es
,
20
02
9
G
h
an
a
22
1
H
b
A
A
,H
b
SS
,
H
b
SC
,
O
th
er
*
M
ed
ia
n
31
(8
–7
5)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
Y
es
,
al
l
6
w
it
h
H
b
SS
(n
=
2)
an
d
H
b
SC
(n
=
4)
D
es
cr
ip
ti
ve
cr
o
ss
se
ct
io
n
al
G
as
sa
ye
et
al
.,
20
00
6
2
R
ep
u
b
li
c
o
f
C
o
n
go
13
H
b
SS
N
R
(N
R
,
4–
62
)
N
A
N
A
U
SS
N
A
R
et
ro
sp
ec
ti
ve
re
vi
ew
o
ve
r
5
ye
ar
s
Y
et
u
n
d
e
an
d
A
n
ya
eg
b
u
,
20
01
5
5
N
ig
er
ia
98
H
b
SS
N
R
,
(N
R
,
30
–5
2)
P
C
V
:
24
(N
R
)
N
A
M
an
u
al
p
al
p
at
io
n
35
0
C
ro
ss
se
ct
io
n
al
A
b
ja
h
an
d
A
ke
n
’O
va
,
20
03
3
7
N
ig
er
ia
70
H
b
SS
,
H
b
SC
,
H
b
A
A
N
R
(N
R
,
15
–5
4)
N
A
N
A
M
an
u
al
p
al
p
at
io
n
H
b
SS
:
50
H
b
SC
:
67
C
as
e-
co
n
tr
o
l
st
u
d
y
D
u
ro
si
n
m
i
et
al
.,
20
05
1
3
N
ig
er
ia
71
H
b
SS
M
ed
ia
n
21
(1
6–
48
)
P
C
V
:
24
(0
1)
43
(N
R
)
M
an
u
al
p
al
p
at
io
n
26
8
C
as
e-
co
n
tr
o
l
st
u
d
y
O
la
n
iy
i
an
d
A
b
ja
h
,
20
07
1
0
5
]
N
ig
er
ia
22
0
H
b
SS
,
H
b
SC
24
7
(8
7,
12
–6
0)
P
C
V
:2
23
(5
2)
N
A
M
an
u
al
p
al
p
at
io
n
H
b
SS
:
20
2
H
b
SC
:
25
9
C
ro
ss
se
ct
io
n
al
K
o
ti
la
et
al
.,
20
00
6
5
N
ig
er
ia
50
H
b
SS
20
(N
R
,
N
R
)
N
A
74
(3
6)
M
an
u
al
p
al
p
at
io
n
16
C
ro
ss
se
ct
io
n
al
A
ki
n
o
la
et
al
.,
20
09
4
5
N
ig
er
ia
15
4
H
b
SS
,
H
b
SC
22
5
(7
3,
N
R
)
P
C
V
:
H
b
SS
:
23
(3
7)
H
b
SC
:
29
(3
8)
N
A
M
an
u
al
p
al
p
at
io
n
H
b
SS
:
17
2
H
b
SC
:
19
2
R
et
ro
sp
ec
ti
ve
re
vi
ew
T
o
lo
-D
ie
b
ki
l e
et
al
.,
20
10
4
3
Iv
o
ry
co
as
t
48
H
b
SS
26
1
(N
R
,
21
–5
6)
H
b
:
95
(N
R
)
10
6
(N
R
)
M
an
u
al
p
al
p
at
io
n
0
R
et
ro
sp
ec
ti
ve
re
vi
ew
B
ab
ad
o
ko
et
al
.,
20
12
2
9
N
ig
er
ia
74
H
b
SS
,
H
b
A
A
23
3
(5
3,
N
R
)
P
C
V
:
25
9(
39
)
N
A
U
SS
41
C
as
e-
co
n
tr
o
l
st
u
d
y
O
jo
et
al
.,
20
14
2
7
N
ig
er
ia
40
H
b
SS
,
H
b
A
A
25
2
(2
2,
16
4
0)
N
A
N
A
U
SS
15
0
C
ro
ss
se
ct
io
n
al
O
ko
n
gw
u
et
al
.,
20
18
7
0
N
ig
er
ia
40
H
b
SS
29
3
(8
,1
7–
51
)
N
A
N
A
U
SS
12
5
C
ro
ss
se
ct
io
n
al
F
as
o
la
an
d
A
d
ek
an
m
i,
20
19
3
2
N
ig
er
ia
42
H
b
SS
,
H
b
A
A
29
(8
1,
N
R
)
H
b
:
77
(1
59
)
P
C
V
:2
55
(5
3)
N
A
U
SS
10
0
C
as
e-
co
n
tr
o
l
st
u
d
y
D
R
C
,
D
em
o
cr
at
ic
R
ep
u
b
li
c
o
f
C
o
n
go
;
H
b
,
H
ae
m
o
gl
o
b
in
;
H
b
F
,
H
ae
m
o
gl
o
b
in
F
N
A
,
n
o
t
as
se
ss
ed
;
N
R
,
n
o
t
re
p
o
rt
ed
;
N
R
C
,
n
o
re
co
rd
;
;
P
C
V
,
p
ac
ke
d
ce
ll
vo
lu
m
e;
P
G
S,
p
er
si
st
en
t
gr
o
ss
sp
le
n
o
m
eg
al
y;
U
SS
,
u
lt
ra
so
u
n
d
sc
an
.
*P
at
ie
n
ts
w
it
h
ab
n
o
rm
al
el
ec
tr
o
p
h
o
re
ti
c
p
at
te
rn
in
cl
u
d
in
g
H
b
A
S,
H
b
A
C
,
H
b
C
C
;
†
Si
ck
le
ce
ll
d
is
ea
se
p
h
en
o
ty
p
e
n
o
t
sp
ec
ifi
ed
.
Review
6 ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd
controls (HbAA). In all, 45 studies provided prevalence rates
for splenomegaly amongst their study population; we found
substantial variation in the criteria used in defining spleno-
megaly. Based on USS, splenomegaly was defined as the long
axis of the spleen >12 cm in three studies,26–28 and >13 cm
in four studies.29–32 In six studies involving children, using
manual palpation, the authors defined massive splenomegaly
as spleen size of at least 10 cm below the coastal margin dur-
ing steady state condition, and persistent gross splenomegaly
as spleen size of ≥10 cm during steady state.8,15,33–36 In seven
other studies, the Hackett classification was used in grading
spleen size.37–43 In all, 25 studies did not report on the
parameters used to define splenomegaly. Only two studies
(36%) reported an assessment of splenic function. The
method employed in both studies was counting of pitted red
cells using direct interference, phase-contrast microscopy.33,34
Spectrum of splenic complications
Splenomegaly. Of the 45 (818%) studies that provided data
on the prevalence of splenomegaly in patients with HbSS, 19
(422%) consisted of children only, 11 (244%) adults only,
and the remaining 15 (333%) consisted of children and
adult participants. In studies involving only children, the
estimate ranged from 12% in Nigeria and Mali to 732% in
the DRC. Four of these studies determined spleen size using
USS and the remaining 15 by manual palpation. Notably, all
11 studies that provided data on the prevalence of splenome-
galy in the adult SCD population were conducted in Nigeria
(n = 10) and Ghana (n = 1). The estimate ranged from 4%
to 50%. Seven of these studies determined spleen size by
manual palpation and the remaining four by USS. Seven
studies, all from the West African countries of Nigeria
(n = 5), Senegal (n = 1) and Ghana (n = 1), reported on
splenomegaly in individuals with HbSC. The prevalence var-
ied from 4% to 42% in children and adolescent,14,35,44 and
15% to 67% in adults with HbSC respectively.9,37,45,46 Three
other studies, two from Northern Africa47,48 and one from
West Africa14 reported data from individuals with HbS-b-
thal0 and HbS-b-thal+ (Table I). In these studies the preva-
lence of splenomegaly ranged from 54% to 88%.14,48
The relationship between spleen size and age was
described in 17 studies (Table II14,26,28,34,36,38,44,46,49–
55,102,103). In studies involving children only, persistence of
the spleen beyond the age of 5 years was noted in most of
the patients with SCD.14,26,49,50 In studies with a mixed pop-
ulation of adults and children, while some demonstrated
decreasing spleen size with increasing age,34,51–53 a few
showed a steady increase in the spleen size up to the sec-
ond54 and third decade46 before the size began to decline. In
one study involving adults with SCD aged >30 years, a third
of the patients still had a palpable spleen.55 Three studies
used USS to compare the spleen sizes in patients with SCD
with those of normal controls.28,46,54 In one of these studies
involving children (age range, 2–17 years), the mean (SD)
spleen length in patents SCD was 9767 (3961) cm, while
that of the controls was 8084 (1689) cm (P < 005).54 In
another report, the mean (SD) longitudinal length of the
spleen in patients with SCD (age range, 3–47 years) was
1017 (18) cm, while in the controls was 956 (13) cm
(P < 002).46 In the third study, the mean splenic volume
and anterior–posterior diameter in patients with SCD (age
range, 0–30 years) was 2673 cm3 and 463 cm, and differed
significantly from the values in the controls of 1613 cm3
(P = 0001) and 412 cm (P = 0048) respectively. However,
there was no significant difference between the spleen length
(P = 0659) and transverse diameter (P = 0433).28
Hypersplenism. Only four studies provided information on
hypersplenism. This was defined in one of the studies as sple-
nomegaly of at least 5 cm in association with haemoglobin
level of <10 g/l from baseline value, low platelets
(<200 9 109/l) and increased reticulocytes (>150 9 109/l)
observed on at least two occasions in the absence of any other
cause of hyperhaemolysis.14 The prevalence of hypersplenism
was generally low across all studies. Two studies involving
children in Nigeria and Senegal reported rates of 01%56 and
5%14 respectively. Similar figures of 1%57 and 42%13 were
also reported in the adult studies in Nigeria and the DRC
respectively. Improvement in the haematological indices after
splenectomy was observed in three studies.13,14,56
Acute splenic sequestration crisis (ASSC). Only six studies
from four countries reported on the occurrence of ASSC.
This was defined in two of the studies as sudden enlargement
of the spleen accompanied by worsening anaemia, requiring
immediate blood transfusion.14,58 The highest prevalence of
273% was reported from Nigeria,59 whereas, two studies,
from Senegal60 and Congo41 reported a prevalence rate of
7%. The prevalence was low at 3% in a study from the
Republic of Benin,58 and 2% in two studies from Senegal14
and the DRC.57 Two studies provided information on ASSC-
related mortality in their patient population; in both studies,
all 11 deaths recorded were related to non-availability of
blood for transfusion.58,59
Surgical splenectomy. A total of eight studies reported data
on splenectomy across six countries including Nigeria
(n = 3), Algeria (n = 1), Senegal (n = 1), Ivory Coast
(n = 1), Togo (n = 1) and the DRC (n = 1). The indications
for splenectomy included hypersplenism in three studies,13,14,56
therapeutic for symptomatic splenomegaly in two studies48,61
and drainage of splenic abscess in one study.62 In one other
study, splenectomy was performed following traumatic rupture
of the spleen in five patients and as prophylaxis in three other
patients.40 The indication for splenectomy was not indicated in
one study.43 In the small series from Togo, the authors
reported on eight children with SCD (five HbSS and three
HbSC; age range 6–13 years), who underwent splenectomy
between 1987 and 2004. All were on prophylaxis with penicillin
Review
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Table II. Summary of studies that reported on the variation in spleen size across different ages (n = 17).
Country
Study
year
Study
size
Prevalence of
splenomegaly,
% Summary of findings Reference
1. Studies involving children only
Gabon 1996 302 330 A third of the patients with SCD still had splenomegaly beyond 5 years of age. Thuilliez et al.49
Kenya 2009 124 330 The peak prevalence of splenomegaly occurred in the age group of 6–8 years.
The largest mean spleen size of 48 cm was seen in the age group of
8–10 years. However, there were no significant
relationship between spleen size and age
Sadarangani et al.50
Senegal 2010 698 HbSS: 201
HbSC: 419
HbS-b-thal:
570
The prevalence of splenomegaly showed a steady increase from infancy
up to the age of 10 years before it started decreasing
Diagneet al.14
Nigeria 2012 415 HbSS: 317
HbSC: 333
A relatively stable prevalence of palpable spleen, occurring in about a
third of patients until the age of 15 years was observed before
it started dropping.
The patients with HbSC had a higher frequency of splenomegaly
between the ages of 5 and 14 years
Brown et al.44
DRC 2013 90 378 Splenomegaly was more common in those aged <5 years (617%) of
age compared to those >5 years (116%)
Aloni et al.102
Nigeria 2014 150 353 Splenomegaly persisted into older age patients. The prevalence of splenomegaly
among children with SCD who were aged >10 years was 113%
Abdullahi et al.26
Nigeria 2017 200 535 The splenic volume was higher in the age group of ≥12 years and lowest
in the age group of 1–2 years.
Yakubu et al.,103
Nigeria 2018 105 260 All patients aged <8 years had their spleen detectable on USS, while 4
out of the remaining 44 patients aged >8 years had autosplenectomy
Akinlosotu et al.36
2. Studies involving children and adults
Nigeria 1982 210 550 The spleen size decreased progressively with increasing age: 55% for <5 years,
45% for 510years and 18% for >10years
Kaine51
Nigeria 1993 310 230 Frequency of splenomegaly across the age groups was: 203% for <5 years;
257% for 6–10 years; 237% for 11–15 years; and 179% for >15 years. No
significant differences in the mean ages of those with or without
splenic enlargement was observed
Adekile et al.34
DRC 1996 591 440 Splenomegaly rarely occurred before 3 years of age in the patients with SCD
compared with normal control, but persisted longer in the SCD
group compared with normal control
Tshilolo et al.38
Nigeria 2001 91 NR The longitudinal spleen length increased continuously up to the age
of 30 years. A reduction in the coronal diameter after the age of 30 years
was the only indicator of splenic size reduction.
Olatunji et al.46
Nigeria 2015 220 23 Splenomegaly was confined to children aged <10 years. A third of the
study group had a normal spleen and most belonged to the <5-years
age group, while one-third of the patients had autosplenectomy and
most belonged to the adolescent group.
Akpan52
Nigeria 2015 104 331 The spleen of SCD subjects generally had undulating variations in size
increasing rapidly from 2 years of age to the childhood/ adulthood
transitional age of 18 years. At >18 years, there was a mixture
of sharp reduction and increase in spleen size in an undulating
form up to the age of 58 years.
Eze et al.54
Nigeria 2018 237 NR The mean spleen length of SCD patients in this study was enlarged in
the age group of 1–10 years; a progressive decrease was observed
with each successive age group afterwards.
Ugwu et al.53
Nigeria 2019 100 310 The largest spleen length and volume was recorded in the age group of
5–9 years, being twice the dimension compared to the 0–4-years age group.
Ezeike28
3. Studies involving adults only
Nigeria 2001 98 350 More than one-third of the study population had palpable
spleen despite an average age of ≥30 years.
Yetunde et al.55
DRC, Democratic Republic of Congo; NR, Not reported; SCD, sickle cell disease; USS, ultrasound scan.
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V, and received pre- and postoperative vaccination against
pneumococcus, meningococcus, and Haemophilus influenzae b.
There was a reduction in their transfusion requirement when
followed-up for 3 years. In another small series from Eastern
Nigeria, the authors reported on 17 patients who underwent
splenectomy over a 12-year period for various conditions
including patients with SCD with splenomegaly (n = 5;
29%).61 The outcome of surgery was uneventful and none of
the patients with SCD required further blood transfusion when
compared to the preoperative period.
Splenic rupture. Traumatic rupture of enlarged spleen was
reported in five out of eight patients with SCD who under-
went splenectomy as described in a retrospective review con-
ducted over a 17-year period from Togo.40 The complication
occurred in three patients with HbSS and two with HbSC.
Clinical examination on presentation revealed evidence of
peritoneal irritation and ascites; abdominal USS confirmed
rupture of the enlarged spleen. All the patients had a total
splenectomy performed.
Splenic abscess. Two studies from Nigeria and the DRC
reported on splenic abscesses. In one of these studies, a
case report from Nigeria, the abscess was treated by
laparotomy and surgical drainage and the spleen pre-
served.63 Whereas, splenectomy was performed in all three
patients with SCD with splenic abscess from the DRC
study.62
Splenic infarction and calcification. Only one study each,
reported on splenic infarction54 and splenic calcification.30 In
both studies, these complications were asymptomatic and
detected during USS in steady state patients with HbSS.
Autosplenectomy. In all, 16 studies provided information on
autosplenectomy. This was defined as the non-visualisation of
the spleen on USS in the absence of surgical splenectomy by
most of the studies. The reported prevalence varied from 4%
to 20% among children, and 20–54% among adult patients
with SCD.
Other associations with spleen size in patients with SCD
Splenic function. Although only two of the 55 studies
reported on spleen function, both studies showed increased
spleen size was associated with retained function.33,34 One
of the studies was a multicentre study, involving seven
centres across Nigeria, and a comparative arm in the
USA.34 The mean pitted erythrocyte count was 43% in
patients with HbSS with splenomegaly and 123% in those
without splenomegaly (P = 0001),33 indicating that spleen
function was better in those with splenomegaly compared
to those without. The mean pitted erythrocyte count was
111% in patients HbSS compared to 18% in the HbAA
population (P = 0001).33
HbF level. While 12 studies provided results for HbF level
in their patients with SCD, only five of these studies evalu-
ated the relationship with spleen size. Three of these studies
from Nigeria,36 Uganda64 and Senegal14 found no significant
relationship between spleen size and HbF level in children
with HbSS. In contrast, two other studies conducted in Nige-
ria amongst adults with HbSS, reported a parallel increase in
HbF level with increased spleen size.13,65 In two studies, one
involving children35 and the other mixed population of chil-
dren and adults,57 the authors indicated that 54% and
292% of their study population were on hydroxyurea respec-
tively. However, no relationship between spleen size and
hydroxyurea therapy was mentioned in either study.
Alpha thalassaemia trait. Two out of the 55 studies evalu-
ated the association between alpha thalassaemia trait and
spleen size. One of the reports from the DRC indicated that
patients with the alpha-thal-2 deletion were more likely to
have splenomegaly.66 However, the second study from Nige-
ria showed that 333% of patients with HbSS with splenome-
galy were heterozygous for alpha-thal-2 deletion compared to
390% for those without splenomegaly; suggesting alpha-thal-
2 deletion was not related to splenomegaly.34
Haematological parameters. There was no consistent associa-
tion between spleen size and haematological parameters
among the studies. For example, while some studies found a
negative correlation between haematocrit and spleen size,14,44
one found a positive correlation,32 and others found no cor-
relation between the two variables.13,46 Similarly, splenome-
galy was associated with cytopenia in some studies,15,26,35 but
not others.53 Likewise, the reticulocyte count increased with
increasing spleen size in one study,26 while another report
found no relationship between the spleen size and reticulo-
cyte count.13
Association between spleen size and infections
Splenomegaly was noted in 16 studies from six countries that
reported on the frequency of bacterial and malaria infections in
patients with SCD (Table III)[8,13,34,35,37–39,41,47,50,59,67–70,102].
Most of these studies (n = 11) involved children. Malaria diag-
nosis was based on peripheral blood smear in most of the
reports. The prevalence of symptomatic malaria was highest in
Nigeria and the DRC at >50%, compared to prevalence rates
from Mali (4%), Kenya (6%), Tanzania (3%) and Uganda
(97%). Eight studies reported on bacterial infections; three of
these studies reported using blood culture for diagnosis. The
reported prevalence rates were 23.8%35 and 256%59 fromNige-
ria, and 28% from Uganda.67 The remaining five studies pro-
vided no clear description of how infection was diagnosed.
Among the 15 studies reporting on both malaria and bac-
terial infections, 10 evaluated the relationship between spleen
size and infections (Table III). Three of these studies indi-
cated no relationship between the frequency of malaria
Review
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parasitaemia or parasite density, clinical malaria and spleen
size,13,50,68 while one study reported a higher parasite density
in patients with normal-sized or enlarged spleens compared
to those with autosplenectomy.69 Three other studies men-
tioned a direct association between increasing spleen size and
levels of serum IgM and anti-malaria IgG.8,34,37 The spleen
size was also reported to have decreased following treatment
with anti-malaria therapy.8
One study evaluated the relationship between splenome-
galy and bacterial infections,67 while two studies evaluated
the association between autosplenectomy and risk of infec-
tions69,70 (Table III). Notably, the relationship between risk
of infections and spleen function was not evaluated in two of
the studies that assessed function.
Discussion
In the present review, we identified 55 studies with data on
various forms of splenic complications among patients with
SCD in Africa. Several studies [n = 45 studies (818%)]
described splenomegaly either by palpation or imaging in
patients with SCD, with a prevalence of 12–73% among chil-
dren and 4–50% among adults with HbSS. Amongst studies
involving patients with HbSC, the prevalence of splenome-
galy varied from 43% to 33% among children and 19–67%
among adults. The reported rates in the HbSS population
from the present review appear high compared to the figures
of 5–19% reported from the USA in children and young
adults with HbSS.71,72 Splenomegaly in patients with SCD in
Africa appears to be less common than in the Middle East,
where the occurrence of splenomegaly in patients with SCD
ranges from 69% to 82% across all age groups.73–75 This may
be attributed to the inclusion of individuals with HbS-b-
thal+ in studies from this region.
In patients with SCD, the spleen commonly enlarges dur-
ing childhood, but then undergoes autosplenectomy by about
5 years of age due to repeated attacks of vaso-occlusion and
infarction.76 A palpable spleen is unusual beyond this age in
patients with HbSS in the USA and Europe,6,77,78 and only
few reports from the West have documented persistence of
the spleen beyond childhood.72 However, this was not what
we observed in African patients with SCD in the present
review. We noted persistence of the spleen into late child-
hood and adulthood across several studies. In one of adult
studies, comprising patients with SCD aged ≥30 years, more
than a third still had an enlarged spleen.55 Indeed, haemoglo-
binopathies accounted for 3% of the causes of massive sple-
nomegaly in adults patients in Ghana.9 This finding indicates
that the late persistence of spleen in patients with SCD in
Africa is comparable to what is observed in the Middle East,
where a large number of adult patients still have a palpable
spleen.74,79 In their report, Al-Salem et al.74 observed that the
spleen size increased with age in their patients with SCD
until ~40 years of age before slowly decreasing.
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The persistence of splenomegaly in patients with SCD in
Africa has been attributed to exposure to bacterial and par-
asitic infections, in particular malaria infection. It is sug-
gested that the parasite causes hyperplasia of the
reticuloendothelial tissues in the host spleen that counteract
the natural progression to autosplenectomy, and hence the
persistence of the spleen.80 This view is supported by
reports from the present review that documented increasing
IgG anti-malaria antibody titre with increasing spleen
size,34,37 high malaria parasite density in children with sple-
nomegaly compared to those without69 and significant
reduction in the spleen size after treatment with the anti-
malaria drug proguanil.8 Additionally, significantly high
IgM values for children with HbSS with persistent spleno-
megaly when compared with those without splenomegaly
was observed and the splenic reticuloendothelial function
was intact in some patients with HbSS with splenome-
galy.33,34 Taken together, the late persistence of the spleen
beyond childhood in patients with SCD in Africa may rep-
resent highly active immune response mechanisms against
malaria and other infective organisms in the region. We
also observed that, all the studies that provided data about
the persistence of splenomegaly in adults with SCD were
from the West African countries of Nigeria and Ghana.
This raises the question as to whether the persistence of
splenomegaly in SCD in Africa could also be due to geo-
graphical variation. Nevertheless, few studies in the present
review found no association between splenomegaly and
malaria parasitaemia or episodes of clinical malaria in both
children and adults.13,50,68 Given the number of studies that
provided data on the prevalence of splenomegaly in SCD
(n = 35), and the limited number of studies exploring the
association between spleen size and infections (n = 10),
along with the conflicting findings from these reports, fur-
ther studies are needed to ascertain the relationship between
splenomegaly and the risk of infections in SCD in Africa.
Reports from other parts of the world suggest that the
persistence of splenomegaly is linked to modifiers of dis-
ease severity such as co-inheritance of alpha thalassaemia
trait and high HbF.81,82 The high HbF level, by its amelio-
rating influence on the sickling process, may play a role in
the persistence of splenomegaly. However, the effects of
these factors remains unclear in the African setting as evi-
denced by the present review, as only two of the nine
studies that evaluated the level of HbF showed an associa-
tion with presence of splenomegaly.13,32 The two studies
that provided information about the co-inheritance of
alpha thalassaemia trait and splenomegaly had conflicting
findings.34,66
Splenomegaly-related complications
The present review highlighted that the presence of an
enlarged spleen may predispose patients with SCD to further
morbidities as described below:
Acute splenic sequestration crisis (ASSC). Splenomegaly was
complicated by ASSC in six studies and in most of these stud-
ies (n = 5), the reported prevalence was <10%. This is lower
than reported in children from other parts of the world83,84
and in adults with SCD.73 In a cohort of 216 children with
HbSS followed since birth, 52 (24%) had at least one episode
of ASSC over the study period of 6 years.85 Also, a total of 437
episodes (006/patient-year) of ASSC was reported over a 9-
year period in the French cohort.83 ASSC also seems to be less
frequent in patients with SCD in Africa compared to the Mid-
dle East, a region with comparable rates of enlarged spleens
persisting into adulthood.73,75,81 The low report of ASSC in
Africa may be related to the late age of patients recruited in
most of the studies. It could also be linked to the expression of
different haplotypes across the geographical regions.
Regular clinical examination and parental education to
identify acute enlargement of the spleen in febrile patients
can facilitate prompt diagnosis of suspected cases. Urgent
treatment with top-up transfusion or red blood cells
exchange is mandatory, as delays can lead to circulatory col-
lapse and death from acute anaemia as evidenced in studies
from Nigeria59 and the Republic of Benin58 that provided
data on ASSC-related mortality. All the ASSC-related deaths
(n = 4) occurred during the first year of the Benin study,
which was designed to determine the effect of a comprehen-
sive clinical care programme on disease course in patients
with SCD. With sustained and intensive parental education
on spleen palpation, no other death was recorded in the
remaining 4 years of the study.58
Hypersplenism. Only a few studies provided information on
hypersplenism, and within these studies, the reported preva-
lence rates were low (<5%). The chronic sequestration of
blood within the enlarged spleen and the accompanying red
cell haemolysis results in cytopenia. The increased transfu-
sion need linked to hypersplenism was the main indication
for splenectomy in most of the studies in the present
review.13,14,56 Also, the resulting expansion in erythropoietic
drive to compensate for the excessive haemolysis imposes a
high metabolic requirement in patients with SCD and may
interfere with normal growth in children.86 This is of partic-
ular concern in patients with SCD in most low-income
countries of Africa where malnutrition is high, because any
additional malnutrition from increased demand can exacer-
bate the susceptibility to infection.87
Surgical splenectomy. A total of 30 patients had splenectomy
performed across 10 studies over a four-decade period in the
present review. This is low compared to reports from the
Middle East, where splenectomy was performed in 44 (20%)
patients (age range, 4–52 years) with SCD over a 4-year per-
iod79 and 134 children (mean age, 76 years) over a 14-year
period for various splenic complications.10,88 The splenec-
tomy rate in a USA study [nine children (8%)] aged
>12 years72 was higher than that in any study in our present
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review. Due to the better availability of specialist surgical
expertise, as well as conjugate vaccine89 and prophylactic
antibiotics 90 in developed countries, splenectomy is more
likely to be considered feasible across all age groups of
patients with SCD.91 However, in Africa, where these
resources are limited, coupled with the high burden of infec-
tion, surgeons may be reluctant to perform splenectomy in
patients with SCD. The operative risk of removing an
enlarged spleen is also high when blood and components for
transfusion may not be reliably available. General anaesthesia
may induce vaso-occlusive crisis, therefore, maintenance of
optimal oxygenation and hydration intraoperatively and min-
imising anaesthetic duration is critical.40,61
Despite the limited data on splenectomies performed in
patients with SCD in Africa, most of the studies [n = 5
(833%)] reported improved clinical symptoms and haemato-
logical parameters following the procedure. Two studies
reported absence of infection-related complications in the
post-splenectomy period after 18 months56 and 3 years40 of
follow-up in their patients; while the remaining eight studies
did not provide information about the risk of infection post-
splenectomy. Careful patient selection and adequate preven-
tive measures before and after splenectomy to control for
infections are crucial to improve the outcome.
Assessing spleen function in SCD in Africa and
implication for future research
The two studies that provided information on spleen func-
tion, noted that most of the patients with palpable spleen
had lower red cell pit counts, indicating that the splenic
reticuloendothelial function was still preserved.33,34 One of
the studies compared splenic function between patients with
HbSS from a malaria zone (Nigeria) and those living in a
malaria-free zone (USA). Patients with palpable spleens in
both groups had significantly lower pit counts when com-
pared to those without splenic enlargement.34 This would
imply that, although functional asplenia has been described
in patients with SCD with splenomegaly, reticuloendothelial
function is not always compromised. This finding is corrobo-
rated by reports from the Middle East, which also showed
preservation of spleen function into adulthood among
patients with SCD with splenomegaly.73,92 However, in con-
trast reports from the West suggest loss of splenic function
in most patients by the age of 2 years.6,93,94 In view of these
conflicting data across regions, further studies are needed to
fill this gap in knowledge regarding the age and prevalence
of splenic dysfunction in patients with SCD in Africa. Addi-
tionally, several studies have evaluated the role of hydrox-
yurea in improving spleen function in patients with
SCD.95,96 The splenic filtration function was preserved after
3 years on treatment in a third of the patients following
hydroxyurea; starting treatment at a younger age and base-
line spleen function were both associated with a favourable
outcome. Recently, the safety and efficacy of hydroxyurea in
young children with SCD residing in malaria endemic
regions of Africa has been demonstrated.97,98 Therefore, the
development of new tools to assess splenic function or the
optimisation of existing ones in low-income countries can
play a role in identifying those patients who can benefit from
such therapy, especially in Africa, where there is a high
prevalence of diseases such as SCD and malaria that can
affect the spleen concurrently.
Splenic function can be measured using several methods
including liver spleen scintigraphy, enumeration of Howell–
Jolly bodies in red blood cells either manually or by flow
cytometry, and counting of pitted red cells using direct inter-
ference, phase-contrast microscopy.99 Unfortunately, these
tests are not readily available in most low-income settings of
Africa, as evidenced by the scarcity of data in the present
review. A simple method has been described, which is based
on counting red cells containing argyrophilic inclusions using
a light microscope. This method has a good correlation with
the pitted red cells count method and a good inter- and
intra-observer reliability.100 This method may be suitable to
assess splenic function in patients with SCD in Africa, where
resources for spleen scintigraphy and interference phase-con-
trast microscopy are absent.
Strengths and limitations of the present review
The major strength of our present review is the comprehensive
inclusion of many studies reporting on various splenic compli-
cations across Africa. It included articles from non-indexed
journals to avoid publication bias, and there were no age, lan-
guage, or time inclusion restrictions. However, the findings of
the review should be interpreted with caution. The studies
measured spleen size in patients with SCD using different
approaches, which made it difficult to compare reported
spleen sizes among the studies. Criteria used to define some of
the splenic complications and infections were not stated or
were inconsistent. Only a few studies reported on spleen-re-
lated complications, so we were unable to combine the data
to provide pooled estimates for these complications.
Conclusion
In Africa, SCD is a prevalent, chronic condition that places a
high burden on the health services and on patients and their
families. Evidence from the present review indicates that
splenomegaly is prevalent among patients with SCD; how-
ever, splenomegaly-related complications are under reported
and may contribute to significant but unrecognised compli-
cations. The spleen seems to persist longer in patients with
SCD in Africa when compared to their counterparts in the
West, although this maybe similar to what is observed in the
Middle East; however, factors explaining this occurrence may
be different. In patients with SCD in Africa there was less
association between splenomegaly and factors such as HbF
level and the presence of alpha thalassaemia traits compared
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to similar patients in the Middle East; instead, a link between
malaria and splenomegaly seems to be indicated by the data
in the present review. There was evidence of an association
between splenomegaly and retention of the spleen function
in patients with splenomegaly, although the data are limited.
Furthermore, there was no information in any of the studies
in the present review regarding the link between spleen func-
tion and the risk of infection. In Africa, where the majority
of children with SCD may die because of infections and with
splenic dysfunction contributing a significant part, the
importance of detecting those at high risk cannot be over
emphasised. Thus, further studies are needed to fill this gap
in knowledge regarding the age and prevalence of splenic
dysfunction in patients with SCD in Africa. Such knowledge
can be employed in the management of infection risk in
patients with SCD and ensure a more effective use of the
limited resources available.
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